Table 1 Demographic characteristics of patients included in the analysis
Variables | Overall (n = 94) |
|---|---|
Age, years | 78.70 ± 7.76 |
T stage | |
T0-T1 | 13 (13.8%) |
T2-T4 | 81 (86.2%) |
N stage | |
N0, Nx | 76 (80.9%) |
N1 | 18 (19.1%) |
M stage | |
M0, Mx | 64 (68.1%) |
M1 | 30 (31.9%) |
Treatment protocols | |
ADT | 69 (73.4%) |
Others | 25 (26.6%) |
Prostate-specific antigen, ng/mL | 75.3 ± 57.7 |
Total CD3(+)T lymphocytes, cells/µL | 992.09 ± 395.10 |
CD3(+) CD4(+)T lymphocytes, cells/µL | 587.11 ± 245.23 |
CD3(+) CD8(+)T lymphocytes, cells/µL | 346.55 ± 220.04 |
Total CD19(+)B lymphocytes, cells/µL | 154.50 ± 125.58 |
CD19(+) CD5(+)B lymphocytes, cells/µL | 52.60 ± 59.55 |
CD19(+) CD5(-)B lymphocytes, cells/µL | 101.83 ± 80.68 |
CD3(-)CD16(+)CD56(+)NK cells, cells/µL | 333.05 ± 198.92 |
All-cause mortality | |
5 years | 52 (55.3%) |
8 years | 68 (72.3%) |
10 years | 80 (85.1%) |